These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 25701970)

  • 1. Bosentan for patients with echocardiographic evidence of pulmonary hypertension due to long-standing rheumatic mitral stenosis.
    Vlachogeorgos GS; Daskalopoulos N; Blatsiotis P; Kourbeti IS; Mantas I; Stathopoulos GT
    Hellenic J Cardiol; 2015; 56(1):36-43. PubMed ID: 25701970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No changes in N-terminal pro-brain natriuretic peptide in a longitudinal cohort of patients with systemic sclerosis-associated pulmonary arterial hypertension on therapy with bosentan.
    Rotondo C; Praino E; Nivuori M; di Serio F; Lapadula G; Iannone F
    Int J Rheum Dis; 2017 Jan; 20(1):90-96. PubMed ID: 26218502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension.
    Aypar E; Alehan D; Karagöz T; Aykan HH; Ertugrul İ
    Cardiol Young; 2018 Apr; 28(4):542-547. PubMed ID: 29233198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial.
    Vizza CD; Jansa P; Teal S; Dombi T; Zhou D
    BMC Cardiovasc Disord; 2017 Sep; 17(1):239. PubMed ID: 28874133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.
    McLaughlin VV; Benza RL; Rubin LJ; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubenfire M; Seeger W
    J Am Coll Cardiol; 2010 May; 55(18):1915-22. PubMed ID: 20430262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An open-label, multicentre pilot study of bosentan in pulmonary arterial hypertension related to congenital heart disease.
    Ibrahim R; Granton JT; Mehta S
    Can Respir J; 2006; 13(8):415-20. PubMed ID: 17149459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of endothelin blockade in adults with Fontan physiology.
    Derk G; Houser L; Miner P; Williams R; Moriarty J; Finn P; Alejos J; Aboulhosn J
    Congenit Heart Dis; 2015; 10(1):E11-6. PubMed ID: 24890846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential benefit of bosentan therapy in borderline or less severe pulmonary hypertension secondary to idiopathic pulmonary fibrosis-an interim analysis of results from a prospective, single-center, randomized, parallel-group study.
    Tanaka Y; Hino M; Gemma A
    BMC Pulm Med; 2017 Dec; 17(1):200. PubMed ID: 29237441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bosentan therapy for chronic thromboembolic pulmonary hypertension. A national open label study assessing the effect of Bosentan on haemodynamics, exercise capacity, quality of life, safety and tolerability in patients with chronic thromboembolic pulmonary hypertension (BOCTEPH-Study).
    Ulrich S; Speich R; Domenighetti G; Geiser T; Aubert JD; Rochat T; Huber L; Treder U; Fischler M
    Swiss Med Wkly; 2007 Oct; 137(41-42):573-80. PubMed ID: 17990150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of bosentan on exercise capacity in adults after the Fontan procedure: a randomized controlled trial.
    Schuuring MJ; Vis JC; van Dijk AP; van Melle JP; Vliegen HW; Pieper PG; Sieswerda GT; de Bruin-Bon RH; Mulder BJ; Bouma BJ
    Eur J Heart Fail; 2013 Jun; 15(6):690-8. PubMed ID: 23361871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the endothelin receptor antagonist bosentan on hemodynamics and exercise capacity in Japanese patients with mildly symptomatic pulmonary arterial hypertension.
    Hatano M; Yamada H; Fukuda K; Yoshioka K; Funauchi M; Kuwana M; Sata M; Taniguchi M; Nakanishi N; Saito T; Saji T; Sasayama S
    Heart Vessels; 2015 Nov; 30(6):798-804. PubMed ID: 25028167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bosentan therapy for pulmonary arterial hypertension.
    Rubin LJ; Badesch DB; Barst RJ; Galie N; Black CM; Keogh A; Pulido T; Frost A; Roux S; Leconte I; Landzberg M; Simonneau G
    N Engl J Med; 2002 Mar; 346(12):896-903. PubMed ID: 11907289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pilot Study of Endothelin Receptor Blockade in Heart Failure with Diastolic Dysfunction and Pulmonary Hypertension (BADDHY-Trial).
    Koller B; Steringer-Mascherbauer R; Ebner CH; Weber T; Ammer M; Eichinger J; Pretsch I; Herold M; Schwaiger J; Ulmer H; Grander W
    Heart Lung Circ; 2017 May; 26(5):433-441. PubMed ID: 27816421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.
    Channick RN; Simonneau G; Sitbon O; Robbins IM; Frost A; Tapson VF; Badesch DB; Roux S; Rainisio M; Bodin F; Rubin LJ
    Lancet; 2001 Oct; 358(9288):1119-23. PubMed ID: 11597664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [First clinical experience with endothelin receptor antagonist bosentan used in patients with pulmonary hypertension: results of a one-year study].
    Avdeev SN; tsareva NA; Nekliudova GV; Chuchalin AG
    Ter Arkh; 2013; 85(3):38-43. PubMed ID: 23720841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial.
    Ghofrani HA; Grimminger F; Grünig E; Huang Y; Jansa P; Jing ZC; Kilpatrick D; Langleben D; Rosenkranz S; Menezes F; Fritsch A; Nikkho S; Humbert M
    Lancet Respir Med; 2016 May; 4(5):361-71. PubMed ID: 27067479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution of Patients with Pulmonary Arterial Hypertension Starting Macitentan After the Discontinuation of Other Endothelin-Receptor Antagonists: Results of a Retrospective Study.
    Cadenas-Menéndez S; Álvarez Vega P; Oterino Manzanas A; Alonso Lecue P; Roig Figueroa V; Bedate Díaz P; Ortiz de Saracho J; Cifrián Martínez JM
    Am J Cardiovasc Drugs; 2020 Oct; 20(5):481-487. PubMed ID: 31879844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension.
    Galiè N; Jansa P; Pulido T; Channick RN; Delcroix M; Ghofrani HA; Le Brun FO; Mehta S; Perchenet L; Rubin LJ; Sastry BKS; Simonneau G; Sitbon O; Souza R; Torbicki A
    Eur Heart J; 2017 Apr; 38(15):1147-1155. PubMed ID: 28329315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of echocardiographic variables of right ventricular function with exercise capacity after bosentan treatment in patients with pulmonary arterial hypertension: Results from a multicenter, prospective, cohort study.
    Kim H; Bae Lee J; Park JH; Yoo BS; Son JW; Yang DH; Lee BR
    J Clin Ultrasound; 2017 Jan; 45(1):28-34. PubMed ID: 27619758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology.
    D'Alto M; Romeo E; Argiento P; Sarubbi B; Santoro G; Grimaldi N; Correra A; Scognamiglio G; Russo MG; Calabrò R
    Int J Cardiol; 2012 Mar; 155(3):378-82. PubMed ID: 21081251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.